ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

Solange Peters

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

Share this video  
Similar topics
Related videos
3:32
Accelerate, Coordinate, Evaluate (ACE) cancer care: the CRUK programme streamlining the care pathway
Sara Hiom
1:57
Lung cancer screening in the UK: CRUK, UK NSC, Public Health England & NHS England
Sara Hiom
3:11
The Recovery Package in lung cancer
Josie Roberts
3:36
Single-port VATS for NSCLC: outcomes related to smoking status
John Edwards
2:09
Psychological impact of lung cancer screening
Mamta Ruparel et al.
Lung Cancer, Non-Small Cell Lung Cancer
Denosumab
SPLENDOUR
ESMO 2018
Interview
19th October 2018
More from Solange Peters
Lung cancer immunotherapy trial data to look forward to in 2018
ESMO 2016: From disease treatment to patient care
The open questions surrounding immunotherapy and targeted therapy in lung cancer
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals